Physician profile
Randy Alevi
NPI 1053723452
$2,076.62
in general payments reported to CMS, 2019-2025
11 companies · $133 in 2025
The $133 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $126 · 2021: $1,272 · 2022: $232 · 2023: $168 · 2024: $145 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $975.00 | 2021 | |
| Global Blood Therapeutics, INC. | $382.28 | 2020-2022 | |
| Abbott Laboratories | $282.70 | 2022-2023 | Freestyle Libre 3 |
| Alk-Abello, INC | $167.03 | 2024-2025 | Odactra, Ragwitek, Grastek |
| Cranial Technologies, INC | $75.15 | 2021-2025 | Doc Band |
| Pfizer INC. | $51.89 | 2020-2024 | |
| Glaxosmithkline, LLC. | $51.71 | 2020-2022 | |
| Phadia US INC. | $24.75 | 2023 | Immunocap |
| Alexion Pharmaceuticals, INC. | $24.02 | 2024 | Strensiq |
| Genentech USA, INC. | $21.56 | 2020 | |
| Aytu Biopharma, INC. | $20.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Alevi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.